Antiretrovirals in the Pipeline: And Then There Were ... None?

April 23rd, 2008

Antiretrovirals in the Pipeline: And Then There Were … None?

The flurry of drug approvals that began in 2005 with tipranavir – followed rapidly by darunavir, maraviroc, raltegravir, and most recently etravirine – has been nothing short of astounding. Every experienced HIV clinician now has many patients who are on successful (read: suppressive) treatment for the first time ever. The Vancouver HIV program — wonderfully called “Centre for Excellence” (why couldn’t our clinic have chosen that name?) — reports that the incidence of drug resistance is declining “drastically.” And their experience is not unique, even though their “excellence” moniker might be.

All good news, right? Well, mostly.

The only downside to all this successful treatment is that the incentive for new drug development must be at an all-time low, especially for antiretrovirals with activity against highly resistant viruses. Unless there’s something flying below the radar, I can’t think of a single new drug likely to gain FDA approval in the next 2-3 years that will provide an effective option to people with no options – in other words, for those unlucky few who don’t have at least two fully active drugs available even with today’s extensive choices.

But how many patients are in this category? I suspect it’s not many: a highly unscientific survey identified three — yes, three — such individuals among the 1200 or so cared for in our clinics. The pie chart of virologic outcomes for people being treated for HIV now looks like this: undetectable virus (largest piece), detectable virus but patient not taking meds for any number of reasons (2nd largest piece), and finally, detectable virus, compliant patient, but no treatment options (just a sliver).

So how many patients with “no options” do you care for? What do you do for them and tell them?

Categories: Health Care, HIV, Infectious Diseases, Patient Care
Tags: antiretrovirals, ART, drug development, HIV, resistance

You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Global Cholera-Control Efforts — Progress and Remaining Challenges June 6, 2026

If the current cholera pandemic, which began in 1961, is ever to end, the world will need better cholera vaccines that are effective in young children and global access to safe water and adequate sanitation.

Childhood Vaccine Hesitancy June 4, 2026

Vaccine hesitancy is often driven by safety concerns. Clinician recommendations, presumptive communication, and empathy improve uptake; maintaining trust supports future acceptance and community protection.

War and Famine June 4, 2026

The prevalence of wasting among children in Gaza tracks with Israeli blockades on aid, but war may lead to famine even without such policies. How should starvation be prevented and treated in wartime?

The Unusual Suspects June 4, 2026

A 53-year-old man with Crohn’s disease and psoriasis presented with a 2-day history of headache, slurred speech, nausea, and vomiting. During the previous 2 weeks, he had had yellowing of the skin and eyes and dark urine.

Sudan Virus Disease in Uganda, 2025 June 3, 2026

In January 2025, an outbreak of disease caused by Sudan virus, an ebolavirus, was identified in Uganda. Characteristics of this outbreak are described.

HIV and ID Observations

An ongoing dialogue on HIV/AIDS, infectious diseases,
all matters medical, and some not so medical.

April 23rd, 2008